HER2 mutations in advanced non-small cell lung cancer

This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.

This trial tests a combination of an EGFR inhibitor pill and an intravenous antibody drug conjugate for people with advanced non-small cell lung cancer who have both an EGFR mutation and a HER2 alteration (mutation, amplification, or protein expression). The goal is to see if this combination works better than standard treatments.

This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.

This study tests a combination of two newer drugs (trastuzumab rezetecan and ivonescimab) for advanced non-small cell lung cancer whose cancer cells have a specific HER2 gene change. The trial includes two groups: people who have already tried one round of treatment, and people newly diagnosed who haven't had treatment yet.

This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.

This study uses a special PET/CT scan to see how a radioactive tracer called Zr-trastuzumab collects in your lung cancer cells. The results will help doctors understand which patients with certain HER2 changes might benefit from HER2-targeted treatments.